Nordic Life Science
Nordic Life Science
The latest business news
Advertising
In March, the country released a 5-year plan for the industry. Here’s what’s new. The life science industry is a critical contributor to the Danish economy, employing 38,000 people and
The company will launch GARDair, the first in vitro test for airway allergies at ESTIV2018, the 20th International Congress on In Vitro Toxicology. Removing the need for animal testing and
The European Patent Office has approved a novel patent for LIDDS NanoZolid technology. The company’s patent protection for the drug delivery technology is now extended for at least another nineteen
Located between two lakes, Näsijärvi and Pyhäjärvi, Finland’s Manchester possesses a vibrant ecosystem, supporting life science collaborations across disciplines. In a beautiful Finnish landscape consisting of lakes and nature reserves,
The company has signed an exclusive license agreement with Cipher Pharmaceuticals for MOB-015 in Canada. Cipher will commercialize MOB-015 in Canada upon completed phase 3 studies and registration. Under the
The Umeåbased startup company has been granted 2.2 million EUR from EU Horizon 2020, the EU framework program for research and development. The grant will go to Lipum’s ongoing development of a
Drug & Device development
The first patient has been dosed in a Phase 2 study evaluating the combination therapy of the company’s cancer immunotherapy, CV301, and Roches’s checkpoint inhibitor, atezolizumab (TECENTRIQ), for the treatment
The company announces results from their BORA Phase III extension trial evaluating the long-term safety and efficacy of Fasenra (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who
Moberg Pharma has completed the recruitment of 365 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal
Ozempic consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (i.e. adverse cardiovascular events, MACE) in people
Professor Jan Nilsson’s research team at Lund University has received an additional DKK 1,000,000 funding from the Novo Nordisk Foundation for carrying out preclinical studies for Follicum’s diabetes project based on
Acarix announces that two Swedish hospitals – Kristianstad and Sunderbyn – have evaluated the CADScor System for rule-out of Coronary Artery Disease. The evaluation compares favorably against existing methods and
In March, the country released a 5-year plan for the industry. Here’s what’s new. The life science industry is a critical contributor to the Danish economy, employing 38,000 people and
Advertising
Latest news
The first patient has been dosed in a Phase 2 study evaluating the combination therapy of the company’s cancer immunotherapy, CV301, and Roches’s checkpoint inhibitor, atezolizumab (TECENTRIQ), for the treatment
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
In focus – Nordic cities
Nordic Life Science
The latest clinical trials
The first patient has been dosed in a Phase 2 study evaluating the combination therapy of the company’s cancer immunotherapy, CV301, and Roches’s checkpoint inhibitor, atezolizumab (TECENTRIQ), for the treatment
The company announces results from their BORA Phase III extension trial evaluating the long-term safety and efficacy of Fasenra (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who
Moberg Pharma has completed the recruitment of 365 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal
Ozempic consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (i.e. adverse cardiovascular events, MACE) in people
Professor Jan Nilsson’s research team at Lund University has received an additional DKK 1,000,000 funding from the Novo Nordisk Foundation for carrying out preclinical studies for Follicum’s diabetes project based on
Acarix announces that two Swedish hospitals – Kristianstad and Sunderbyn – have evaluated the CADScor System for rule-out of Coronary Artery Disease. The evaluation compares favorably against existing methods and
AstraZeneca and MedImmune have announced new results from their TULIP 1 Phase III trial for anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (SLE). The trial did not meet
AstraZeneca has announced results from the AERISTO Phase IIIb trial for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). In the trial, Bevespi Aerosphere demonstrated non-inferiority
The Swedish company has announced the results of a preclinical study confirming the potential for its NanoZolid technology for use with STING agonists, a novel cancer immunotherapy treatment. Due to
The latest research news from the Nordic region
Science Article
Researchers at Karolinska Institutet have identified four types of neurons in the peripheral auditory system, three of which are new to science, they report Previously, most of the ear’s nerve
Scientists from the University of Turku have discovered a link between certain genetic mutations, the aggressiveness of prostate cancer, risk of developing the disease and poorer survival rates of patients.
Researchers at Karolinska Institutet have discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. Already over 40 years ago
Professor Lorelei Lingard’s research has contributed significantly to our understanding of how healthcare professionals interact and communicate with each other, which has led to new clinical practices and increased patient
Medical or surgical treatment of severe heartburn prevents cancer of the oesophagus, a study from Karolinska Institutet with almost one million Nordic patients reveals. The results are published in the
The Swedish national government gives clearance to the detailed plan for Science Village at the European Spallation Source (ESS) in Brunnshög, Lund. The Swedish Radiation Safety Authority’s study has given answers